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Abstract 
 
Context 
Pruritus associated with hepatic or renal failure can be a troublesome symptom, 
refractory to treatment, associated with significant physical and emotional distress, and 
reduction in quality of life for patients already burdened with chronic disease.  
Serotonin has been implicated as a possible pathological mediator, and therefore 5HT3 
antagonists have been suggested as a possible therapeutic intervention. 
 
Objectives 
This review of the literature systematically explores the role of ondansetron in the 
management of cholestatic or uraemic pruritus. 
 
Methods 
Electronic databases were systematically searched for randomized controlled trials 
(RCTs) examining the role of ondansetron in cholestatic or uraemic pruritus between 
1966 and 2008. 
 
Results 
Five RCTs were included in this systematic review: three for cholestatic pruritus, and 
two for uraemic pruritus.  All trials examined ondansetron versus placebo, however 
with differing treatment protocols. Overall, three studies showed no benefit to 
ondansetron over placebo, however two studies in cholestatic pruritus showed small 
reductions in pruritus with questionable clinical significance. 
 
Conclusion 
Ondansetron was demonstrated to have negligible effect on cholestatic or uraemic 
pruritus on the basis of a limited number of studies. 
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Running title 
Ondansetron for pruritus 
  
Introduction 
The pruritus associated with hepatic or renal failure can be a further disabling symptom 
in people already dealing with chronic or life-limiting illnesses.  Chronic pruritus can be 
persistent and distressing with significant effects on physical comfort and quality of life, 
with potential psychological, functional and social impact and increased morbidity.1-3  
The pathophysiology of this pruritus is not well understood, however is thought to be 
driven by chronic inflammation involving dedicated unmyelinated C fibres, similar to 
but distinct from pain fibres, stimulated by one or more peripheral pruritogens.  
Mediators suspected to be involved in this process include histamine, endogenous 
opioids and serotonin.2,3  Furthermore, in cholestasis, bile salts, steroid hormones and 
their metabolites, and lysophosphatidic acid have been implicated,3 whilst in uraemia 
chronic skin changes, calcium-phosphorus products, hyperparythyroidism, and dialysis 
efficacy may influence pruritus.2-4 
 
Pharmacological strategies to try to manage itch have targeted these proposed 
pathophysiological mechanisms, and have included antihistamines, antidepressants, 
membrane-stabilisers, rifampicin, thalidomide, opioid antagonists and 5HT3 
antagonists.  Because of the proposed involvement of serotonin in mediating the 
pruritus of cholestasis and uraemia, 5HT3 antagonists have been tried for symptom 
management.  The Australian Therapeutic Guidelines for Palliative Care5 recommend 
sedating antihistamines, doxepin, and paroxetine.  In cholestasis, they also suggest 
rifampicin and ondansetron. The evidence for these recommendations is limited largely 
to case reports, case series and under-powered clinical trials.   
 
The Australian Palliative Care Clinical Studies Collaborative (PaCCSC) was 
commissioned to evaluate the role of ondansetron for chronic pruritis. This systematic 
review is the first step of a process to explore the need for further or more complex 
adequately powered phase III studies.  Therefore the aim of this paper is to systemically 
examine the evidence for the use of ondansetron in the management of pruritus 
secondary to cholestasis or uraemia. 
 
Methods 
 
Search strategy for the identification of studies 
An initial search of MEDLINE, PubMed, EMBASE and CINAHL was undertaken in 
October 2008 using the key words: ondansetron, cholestatic itch, cholestasis, pruritus, 
antipruritics and combinations of these.  Searches were limited to studies in humans.  
Results from the four databases were merged into one file and duplicate results deleted 
from the merged file. 
 
Eligibility criteria 
Only randomized controlled trials comparing the effect of ondansetron to placebo on 
cholestatic or uraemic pruritus in humans were considered.  Only published trials in 
English were considered. 
 
Methods of review 
Two authors independently assessed the abstracts of studies retrieved from the initial 
search.  Abstracts that meet the eligibility criteria were identified for full text retrieval 
and analysis.  The references of full text articles retrieved were hand searched to 
identify any other relevant articles.  Trial quality was assessed using Jadad scores.6 
Differences were settled by consensus. Other data collected included the number and 
characteristics of the participants, the 5HT3 antagonist dose, administration route and 
schedule, outcome measures and results. Given the disparate nature and extent of the 
studies identified, and the quality of their reporting, adherence to the CONSORT 
guidelines was not evaluated.  
 
Results 
 
There were 241 studies identified using the search method, and of those, 80 were 
selected for full text retrieval.  Of the 80 papers retrieved only six studies were 
randomised controlled trials.  One study was published in Turkish, leaving only five 
studies eligible for review (see Table 1).  There were no further relevant articles 
identified by hand search of the references of the retrieved papers.  Significant 
heterogeneity was identified in  study design, underlying diagnosis, route of 
administration of ondansetron, dosage and duration of intervention, and outcome 
measures.  Given these factors it was not possible to combine the data into a meta 
analysis. 
 
Patient population and setting 
Three of the eligible studies examined the role of ondansetron in cholestatic itch, and 
two studies in uraemic itch (see Table 1).   
 
Ninety-one patients were assessed across the five studies, with an average age of 
participants in each of the study groups ranging from 47 to 60 years (overall range of 
27-80 years), and 37% male participation ranging from 16-28% (n=11) in cholestatic 
itch, and 54-63% (n=23) in uraemic itch. 
 
For the cholestatic group, one study had predominantly patients with primary bilary 
cirrhosis, whilst the other two studies had more heterogenous aetiologies.  The average 
bilirubin was 17-63µmol/L in the three studies, with a very large range (5-
1250µmol/L).  For the uraemic group, the aetiology of the renal failure and the 
frequency of haemodialysis was listed in one study, but not the other.   
 
 
Intervention 
The protocols for the use of ondansetron varied significantly.  The protocol with the 
largest number of participants was oral ondansetron/placebo 8 milligrams (mg) three 
times daily followed a washout period and crossover.  However the duration of the 
therapeutic trial before washout and crossover varied from five days to four weeks.  
The study by O’Donohue et al. varied from this by using a loading intravenous 
ondansetron /placebo dose followed by oral maintenance ondansetron/placebo with no 
crossover.7 
 
Outcome measures 
Four studies used 0-10 visual analogue scales (VAS), most commonly reporting mean 
pruritus ratings, however one study reported median ratings,8 and another 
distinguished mean pruritus and mean peak pruritus ratings.9  Another study used a 0-
10 numerical rating scale (NRS), and also incorporated a subjective assessor-rated 
pruritus score using a 0-3 NRS.10  These outcome measures were rated once, twice or 
three times daily.   
 
Two studies also used a measure of scratching activity using a fingernail mounted 
piezo-electric crystal.7,10  Two studies incorporated measurement of additional 
antihistamine use (one oral, one topical) as a surrogate for improvement in pruritus.8,9 
 
Outcomes 
One study found no difference in VAS assessed uraemic pruritus with ondansetron.8  
Two studies found reductions in VAS assessed cholestatic and uraemic pruritus by 21 
and 16% with ondansetron, however this was matched by reductions in the placebo 
group of 22 and 25% respectively.7,11  In contrast, one study showed a modest 
improvement of 1.34 points in peak VAS assessed cholestatic pruritus with ondansetron 
compared to placebo,9 and one study showed minimal improvement of 0.21 points in 
mean NRS assessed cholestatic pruritus.10  Five of thirteen participants also had a 27% 
decrease in subjective assessor-rated pruritus on a 0-3 NRS, with the remaining eight 
showing no difference with placebo.10  The duration of treatment did not affect the 
likelihood of response. 
 
In the studies that measured scratching activity, there was no correlation between 
scratching activity and VAS, and there was no reduction in scratching in the 
ondansetron group compared with placebo.7  Whilst one study showed a small 
reduction in NRS assessed pruritus, there was no associated reduction in scratching 
activity.10   
 
There was no reduction in the use of rescue oral or topical antihistamine as an outcome 
in the two studies that examined this.8,9 
 
Toxicity was not addressed in one study,11, whilst two studies stated no adverse effects 
documented.8,9  However two studies describe high rates of constipation (44-71%), as 
well as cramps, nausea, headache and dizziness as may be expected from a 5HT3 
antagonist7,10    
 
Discussion 
 
In a number of small studies with heterogeneous populations, methods and outcomes, 
there is no evidence for the benefit of ondansetron in the management of uraemic 
pruritus, and scant evidence in cholestatic pruritus.  For the two studies that 
demonstrate benefit in cholestatic pruritus, the effect is small and debatable as to the 
clinical significance to the patient.   
 
Treatment with placebo produced significant reductions in subjective pruritus ratings.  
Whilst this effect may be frequently encountered in trials with subjective symptom 
based outcomes, this makes the demonstration of effect of ondansetron more difficult as 
the benefit needs to be of a magnitude sufficient to have clinical benefit over and above 
the placebo response.   
Objective measurements of scratching activity have been shown to correlate with visual 
observation.12,13  Some studies have also demonstrated correlation between objective 
scratching activity and subjective symptom ratings,14,15 however, scratching activity 
does not always correlate with subjective symptom ratings.16,17  This highlights the 
complex relationship between subjective and objective measures which is not unique to 
itch, but is seen in many symptom related studies, such as pain.  For the patient, whilst 
subjective improvement is important, it’s relationship to objective measurements 
remains variable and a major challenge for research. 
Generalisability 
The reported studies only evaluated stable patients with persistent pruritus in the 
ambulatory setting.  It is not possible to comment on patients with pruritus associated 
with acute hepatic or renal failure – whilst the underlying mechanism may be similar, in 
chronic pruritus there may be central sensitization, as seen with chronic pain states, 
that make persistent pruritus different pathophysiologically and potentially more 
refractory to treatment.18 
 
Limitations 
Any systematic review is limited by the studies available.  Despite evidence of use in 
clinical practice, the underlying studies to support ondansetron for this indication are 
few and inconclusive, thus making it hard to draw absolute conclusions.  Given the 
magnitude and direction of change, even if a meta-analysis were possible, it is unlikely 
to show any net clinical benefit.  
 
The two studies of uraemic pruritus were published in 2000 and 2003.  Progress in the 
management of chronic renal impairment and haemodialysis may mean that the 
symptom profile and responsiveness to treatment of patients on haemodialysis may be 
different from those described in these studies.  For instance, modern day dialysis dose, 
flux and management of haemoglobin, calcium, phosphate and parathyroid hormone 
levels may lead to better dialysis efficacy and reduced secondary hyperparathyroidism 
with subsequent reduced symptom burden.  However there is no indication from these 
studies that ondansetron has a role in uraemic pruritus. 
 
Reporting of toxicity was very poor in all studies, given the rates of toxicity reported in 
the use of 5HT3 antagonists in more than single dose studies in oncology and peri-
operative care.        
 
Implications for practice 
Management of cholestatic or uraemic pruritus should first look to optimize the 
treatment of the underlying condition.  However optimization may not be possible or 
sufficient to ameliorate the pruritus.  Given the multifactorial nature of pruritus and the 
paucity of evidence for effective treatments, treatment may involve a number of 
modalities including topical, systemic and non-pharmacological strategies based on the 
underlying aetiology.  For cholestatic pruritus, consideration should still be given to 
antihistamines, cholestyramine, rifampicin, opioid antagonists, selective serotonin 
reuptake inhibitors and bright-light therapy.2,3  For uraemic pruritus, therapeutic trials 
could include emollients, capsaicin, antihistamines, gabapentin, tricyclic 
antidepressants, thalidomide, opioid antagonists, acupuncture and ultraviolet 
phototherapy.2,4   
 
Implications for research 
Further work is required to understand the pathophysiology of pruritus in both acute 
and chronic cholestatic and uraemic pruritus in order to understand therapeutic targets 
for intervention.  
 
There is a paucity of randomised controlled trials in therapeutic interventions for 
cholestatic or uraemic pruritus.  This is further complicated by the difficulties with 
measuring pruritus subjectively and objectively, and high placebo response rates.  Given 
these difficulties, and findings of this systematic review, the results do not support the 
pursuit of further randomised trials of ondansetron in the treatment of cholestatic or 
uraemic itch.  
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Table 1. Randomised controlled trials of ondansetron in cholestatic or uraemic pruritus. 
 
RCT – randomized controlled trial, PBC – primary biliary cirrhosis, HD – haemodialysis, VAS – visual analogue scale, NRS – numerical rating scale 
 Design n Age 
(range) 
Male Characteristics Intervention Outcomes Jadad 
Muller et al. 
19989 (Austria) 
RCT with 
crossover  
18 Mean 60 
(31-73) 
5/18 
(28%) 
PBC 6/18, hepatitis C 6/18, 
alcoholic cirrhosis 3/18, 
cryptogenic cirrhosis 2/18, 
HCC 1/18 
Mean bilirubin 37µmol/L 
(range 11-760) 
Ondansetron/placebo 
8mg tds po for 7 days then 
crossover  
VAS 0-10 tds (mean & 
peak) 
4 
Ashmore et al. 
20008 (United 
Kingdom) 
RCT with 
crossover 
16 Median 60 
(28-77) 
10/16 
(63%) 
HD (mixed aetiology) 
9pts HD 3x/wk, 7pts HD 
2x/wk 
Ondansetron /placebo 
8mg tds po for 14 days 
then crossover 
VAS 0-10 daily 
(median); rescue 
antihistamine use 
3 
Murphy  et al. 
200311 (United 
Kingdom) 
RCT with 
crossover 
17 Median 59 13/24 
(54%) 
HD (unspecified aetiology) 
No information on HD 
frequency 
Ondansetron/placebo 
8mg tds po for 14 days 
then crossover 
VAS 0-10 bd (mean) 4 
O’Donohue et 
al. 20057 
(United 
Kingdom) 
RCT 18 Mean 55 
(27-80) 
3/19 
(16%) 
PBC 17/19 
Mean bilirubin 63µmol/L 
(range 10-1250) 
Ondansetron/placebo 
8mg IV bolus then 
ondansetron/placebo 8mg 
bd po for 5 days 
VAS 0-10 3hrly 
(mean); scratching 
activity 
4 
Jones et al. 
200710 
(Netherlands) 
RCT with 
crossover 
14 Mean 47 
(29-63) 
3/14 
(21%) 
PBC 7/14, chronic hepatitis 
4/14, other 3/14 
Mean bilirubin 17µmol/L 
(range 5-113) 
Ondansetron/placebo 
8mg tds po for 4 weeks 
then crossover 
Assessor severity 0-3; 
Self-report NRS 0-10 
daily (mean); 
scratching activity 
4 
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